Physician profile
Vikram Kapur
NPI 1063466647
$7,977.38
in general payments reported to CMS, 2019-2025
56 companies · $1,532 in 2025
The $1,532 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $956 · 2020: $798 · 2021: $907 · 2022: $1,119 · 2023: $1,116 · 2024: $1,550 · 2025: $1,532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,198.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,058.32 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $761.66 | 2021-2025 | |
| Novo Nordisk INC | $603.08 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $495.66 | 2019-2023 | Jardiance |
| Amgen INC. | $435.16 | 2020-2025 | Krystexxa, Repatha, Otezla |
| Abbott Laboratories | $391.80 | 2019-2025 | Freestyle Libre 3, Absorb Gt1 |
| Dexcom, INC. | $380.30 | 2021-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $375.16 | 2019-2025 | Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $247.71 | 2022-2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $185.63 | 2019-2022 | |
| Boston Scientific Corporation | $185.11 | 2020-2025 | General - Therapies |
| Edwards Lifesciences Corporation | $164.75 | 2023-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abiomed | $159.60 | 2025 | |
| Janssen Pharmaceuticals, INC | $148.76 | 2019-2025 | Spravato |
| Pfizer INC. | $143.42 | 2019-2025 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikram Kapur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.